PSMA-POSITIVE PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for PSMA-POSITIVE PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new PSMA-POSITIVE PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for PSMA-POSITIVE PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…
Matched conditions: PSMA-POSITIVE PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for tough prostate cancer: HRS-4357 faces off against standard care in major trial
Disease control Recruiting nowThis study tests a new drug, HRS-4357, against current standard treatments for men with a specific type of advanced prostate cancer (PSMA-positive, castration-resistant) that has spread. About 370 men will be randomly assigned to receive either HRS-4357 or a standard therapy. The…
Matched conditions: PSMA-POSITIVE PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC